<- Go Home
MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc., together with its subsidiaries, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer. Its lead program is THIO, a potential cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
Market Cap
$58.0M
Volume
277.5K
Cash and Equivalents
$9.6M
EBITDA
N/A
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$5.99
52 Week Low
$1.40
Dividend
N/A
Price / Book Value
14.11
Price / Earnings
-1.87
Price / Tangible Book Value
14.11
Enterprise Value
$48.4M
Enterprise Value / EBITDA
N/A
Operating Income
-$17.0M
Return on Equity
1131.02%
Return on Assets
-119.60
Cash and Short Term Investments
$9.6M
Debt
N/A
Equity
$3.6M
Revenue
N/A
Unlevered FCF
-$9.9M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium